NeuLogiq platform proves effective for at-home ALS and FTD monitoring

The CNS-102 study, conducted in partnership with the PRECISIONALS initiative at Trinity College Dublin, addressed a long-standing measurement gap in neurodegenerative research. Standard clinical tools like the ALSFRS-R focus primarily on motor decline, often overlooking the cognitive and behavioral shifts that characterize the ALS–Frontotemporal spectrum. The NeuLogiq system integrates a 16-channel wireless dry-sensor EEG headset with tablet-based cognitive tasks to provide a more comprehensive view of patient health.

Over an eight-month period, 28 participants—including those with ALS and FTD—demonstrated high levels of engagement with the technology. Notably, 82% of ALS participants reported the platform was easy to use, and 75% expressed a positive opinion of the experience. The system achieved a 92% data completeness rate, providing objective metrics that matched the sensitivity of clinician-administered batteries.

Beyond usability, the study surfaced exploratory signals that traditional in-clinic assessments missed. Researchers observed longitudinal changes in speech fluency and emotion recognition within the ALS cohort, suggesting that frequent, home-based sampling can capture disease progression nuances that infrequent hospital visits fail to detect. Brian Murphy, founder of Cumulus Neuroscience, emphasized that this combination of high-quality, multimodal data and patient acceptability offers a new foundation for designing sensitive, patient-centered clinical trials. While these findings serve as a proof-of-concept, the team notes that replication in larger cohorts is necessary to confirm the clinical utility of these digital biomarkers.